Boundless Bio Common Net Income
| BOLD Stock | USD 1.09 0.04 3.81% |
As of the 6th of February, Boundless Bio shows the Mean Deviation of 2.14, risk adjusted performance of (0.08), and Standard Deviation of 2.94. Boundless Bio Common technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Boundless Bio Common standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if Boundless Bio Common is priced correctly, providing market reflects its regular price of 1.09 per share. Given that Boundless Bio is a hitting penny stock territory we recommend to closely look at its jensen alpha.
Boundless Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Boundless Bio's valuation are provided below:There are over one hundred nineteen available fundamental signals for Boundless Bio Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Boundless Bio's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 6, 2026, Enterprise Value is expected to decline to about (20.3 M) This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -75.2 M | -78.9 M | |
| Net Loss | -58.8 M | -61.8 M | |
| Net Loss | (4.43) | (4.65) | |
| Net Income Per E B T | 0.88 | 0.78 |
Boundless | Net Income | Build AI portfolio with Boundless Stock |
Analyzing Boundless Bio's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Boundless Bio's current valuation and future prospects.
Latest Boundless Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Boundless Bio Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Boundless Bio Common financial statement analysis. It represents the amount of money remaining after all of Boundless Bio Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Boundless Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boundless Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (65.36 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Boundless Net Income Regression Statistics
| Arithmetic Mean | (60,420,957) | |
| Coefficient Of Variation | (41.80) | |
| Mean Deviation | 16,048,292 | |
| Median | (59,668,000) | |
| Standard Deviation | 25,257,277 | |
| Sample Variance | 637.9T | |
| Range | 103.6M | |
| R-Value | 0.02 | |
| Mean Square Error | 680.1T | |
| R-Squared | 0.0005 | |
| Significance | 0.93 | |
| Slope | 114,773 | |
| Total Sum of Squares | 10206.9T |
Boundless Net Income History
Other Fundumenentals of Boundless Bio Common
Boundless Bio Net Income component correlations
Boundless Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Boundless Bio is extremely important. It helps to project a fair market value of Boundless Stock properly, considering its historical fundamentals such as Net Income. Since Boundless Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boundless Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boundless Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Boundless Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Boundless Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Boundless Bio.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Boundless Bio on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Boundless Bio Common or generate 0.0% return on investment in Boundless Bio over 90 days. Boundless Bio is related to or competes with Q32 Bio, NextCure, Plus Therapeutics, Intensity Therapeutics, Iterum Therapeutics, AN2 Therapeutics, and Pluri. Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene ther... More
Boundless Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Boundless Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Boundless Bio Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 16.75 | |||
| Value At Risk | (4.84) | |||
| Potential Upside | 4.13 |
Boundless Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Boundless Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Boundless Bio's standard deviation. In reality, there are many statistical measures that can use Boundless Bio historical prices to predict the future Boundless Bio's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (2.13) |
Boundless Bio February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (2.12) | |||
| Mean Deviation | 2.14 | |||
| Coefficient Of Variation | (872.12) | |||
| Standard Deviation | 2.94 | |||
| Variance | 8.62 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (2.13) | |||
| Maximum Drawdown | 16.75 | |||
| Value At Risk | (4.84) | |||
| Potential Upside | 4.13 | |||
| Skewness | 0.9407 | |||
| Kurtosis | 2.92 |
Boundless Bio Common Backtested Returns
Boundless Bio Common secures Sharpe Ratio (or Efficiency) of -0.0443, which signifies that the company had a -0.0443 % return per unit of risk over the last 3 months. Boundless Bio Common exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Boundless Bio's Mean Deviation of 2.14, standard deviation of 2.94, and Risk Adjusted Performance of (0.08) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Boundless Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Boundless Bio is expected to be smaller as well. At this point, Boundless Bio Common has a negative expected return of -0.13%. Please make sure to confirm Boundless Bio's day median price, period momentum indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if Boundless Bio Common performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.66 |
Very good reverse predictability
Boundless Bio Common has very good reverse predictability. Overlapping area represents the amount of predictability between Boundless Bio time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Boundless Bio Common price movement. The serial correlation of -0.66 indicates that around 66.0% of current Boundless Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.66 | |
| Spearman Rank Test | -0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Boundless Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Boundless Bio Common reported net income of (65.36 Million). This is 119.15% lower than that of the Biotechnology sector and 193.31% lower than that of the Health Care industry. The net income for all United States stocks is 111.45% higher than that of the company.
Boundless Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boundless Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boundless Bio could also be used in its relative valuation, which is a method of valuing Boundless Bio by comparing valuation metrics of similar companies.Boundless Bio is currently under evaluation in net income category among its peers.
Boundless Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (42.52 M) | ||||
| Shares Outstanding | 22.39 M | ||||
| Shares Owned By Insiders | 11.39 % | ||||
| Shares Owned By Institutions | 57.96 % | ||||
| Number Of Shares Shorted | 52.76 K | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.22 X | ||||
| EBITDA | (64.28 M) | ||||
| Net Income | (65.36 M) | ||||
| Cash And Equivalents | 351.46 M | ||||
| Cash Per Share | 7.68 X | ||||
| Total Debt | 47.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.80 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (60.84 M) | ||||
| Short Ratio | 0.40 X | ||||
| Earnings Per Share | (2.60) X | ||||
| Price To Earnings To Growth | (1.09) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 64 | ||||
| Beta | 2.19 | ||||
| Market Capitalization | 23.5 M | ||||
| Total Asset | 206.41 M | ||||
| Retained Earnings | (201.47 M) | ||||
| Working Capital | 146.25 M | ||||
| Current Asset | 99.64 M | ||||
| Current Liabilities | 104 K | ||||
| Net Asset | 206.41 M |
About Boundless Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Boundless Bio Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boundless Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boundless Bio Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio Common is a strong investment it is important to analyze Boundless Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio's future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could Boundless diversify its offerings? Factors like these will boost the valuation of Boundless Bio. Projected growth potential of Boundless fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Boundless Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Boundless Bio Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio's value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Boundless Bio's market value can be influenced by many factors that don't directly affect Boundless Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Boundless Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Boundless Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Boundless Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.